Weekly News Recap #Phispers | PharmaCompass.com

Merck inks US$ 3.3 bn cancer deal with LaNova; vaccine makers’ stocks tumble after Trump picks RFK Jr to head HHS

This week, Merck struck a strategic US$ 3.3 billion deal with LaNova Medicines for a promising cancer drug, and also demonstr...

Impressions : 795

Astra invests US$ 2 bn in US R&D; key AbbVie asset from US$ 8.7 bn Cerevel buy flunks phase 2 trials

This week’s Phispers is packed with news about deals. First, AstraZeneca announced a US$ 2 billion investment in the...

Impressions : 499

Astra faces probe in China; AbbVie, EvolveImmune ink potential US$ 1.4 bn deal; EC levies US$ 503 mn fine on Teva

In this week’s Phispers, AstraZeneca faces a major crisis in China as its president Leon Wang is under investigation in w...

Impressions : 767

AbbVie strengthens Alzheimer’s pipeline with US$ 1.4 bn Aliada buyout; Roche expands gene therapy pact with Dyno

This week’s Phispers is packed with latest developments in the field of Alzheimer’s disease, owing to a conference ...

Impressions : 682

Sanofi to sell 50% stake in Opella to CD&R, to retain French workforce; AbbVie bags FDA nod for Parkinson’s therapy Vyalev

In this week’s Phispers, Sanofi has entered into exclusive talks with US private equity firm CD&R to sell a controlling 5...

Impressions : 758

Lundbeck acquires Longboard for US$ 2.6 billion; Roche’s Itovebi bags FDA nod for breast cancer

This week’s is a double dose Phispers, as we return from a one-week break due to CPhI Worldwide. The fortnight saw severa...

Impressions : 851

BMS med wins landmark FDA nod for schizophrenia; Sanofi’s Dupixent approved to treat COPD

In this week’s Phispers, the US Food and Drug Administration (FDA) approved Bristol Myers Squibb’s groundbreaking s...

Impressions : 773

Sanofi gets two bids valuing its consumer unit at US$ 17 bn; Pfizer pulls SCD drug from market

In news this week, Sanofi is considering the sale of its consumer health unit and has received binding bids valuing the divisi...

Impressions : 1063

FDA panel votes against Intercept’s liver med Ocaliva; Lilly’s Ebglyss wins approval for eczema

Intercept Pharmaceuticals faced a major setback as a US Food and Drug Administration (FDA) panel voted against the confirmato...

Impressions : 934

GSK’s COPD, long-acting asthma drugs score late-stage wins; Novo’s weight-loss drug Saxenda found to be safe in kids

GSK scored a significant late-stage win with its asthma drug Nucala in treating chronic obstructive pulmonary disease (COPD). I...

Impressions : 629

FDA approves Emergent’s smallpox vaccine for mpox; Lilly inks up to US$ 1 bn deal with Haya to target obesity

This week saw the US Food and Drug Administration (FDA) respond to the global monkeypox (mpox) public health emergency by expan...

Impressions : 987

Lilly, Pfizer move to sell drugs directly to consumers; blast at Indian drug factory kills 17

An Indian factory that makes drugs for export to the US and other Western nations saw an explosion, caused by a chemical solven...

Impressions : 1493

IRA price talks conclude, three meds dominate savings; Gilead’s Livdelzi from CymaBay buyout gets FDA okay

This week, the Biden-Harris Administration said it has concluded price negotiations for 10 drugs under the Inflation Reduction ...

Impressions : 639

FDA rejects first MDMA therapy to treat PTSD; Merck, Curon ink up to US$ 1.3 bn deal for next-gen bispecific antibody

The US Food and Drug Administration (FDA) has declined to approve an MDMA-assisted therapy from Lykos Therapeutics to treat pos...

Impressions : 1331

FDA approves first ever T-cell receptor gene therapy from Adaptimmune, Servier’s brain tumor pill

This week, Adaptimmune clinched gold when it secured the first-ever US Food and Drug Administration (FDA) approval for a T-cell...

Impressions : 808

Boehringer boosts immune-oncology pipeline with US$ 1.3 bn Nerio buy; Pfizer adds US$ 1 bn to 2024 outlook

This week, the world’s largest private pharma company, Boehringer Ingelheim, acquired Nerio Therapeutics for up to US$ 1....

Impressions : 707

Merck’s RSV jab shows efficacy in infants; Novo-Lilly weight loss rivalry intensifies as China okays tirzepatide

This was a week when the US President Joe Biden ended his reelection bid, after giving America the Inflation Reduction Act that...

Impressions : 942

US Senate passes bipartisan bill to cut pharma patent abuses; Ipsen inks another ADC deal

This week, a bill heralded as “critical” to help “end anti-competitive practices” was passed by the US ...

Impressions : 1182

Lilly to acquire IBD drug developer Morphic for US$ 3.2 bn; Pfizer’s R&D chief to step down

This week saw Eli Lilly strike yet another deal as it announced the acquisition of Morphic Holding for about US$ 3.2 billion, t...

Impressions : 946

Lilly’s Alzheimer’s drug gets FDA nod; GSK buys rights to mRNA vaccines from Curevac for US$ 1.56 bn

This week, the US Food and Drug Administration (FDA) finally approved Eli Lilly’s Alzheimer’s drug donanemab after ...

Impressions : 761

Novo invests US$ 4.1 bn to boost Wegovy, Ozempic supply; Verona’s COPD therapy bags FDA nod

This week saw a couple of developments in the lucrative US market for glucagon-like peptide-1 (GLP-1) drugs that treat diabetes...

Impressions : 936

Merck wins FDA nod for pneumococcal vaccine; Roche partners Ascidian to develop novel gene therapies

This week saw the US Food and Drug Administration (FDA) approve Merck’s next-generation pneumococcal vaccine for adults. ...

Impressions : 1031

FDA panel backs Lilly’s Alzheimer’s drug; agency approves Ipsen’s med to treat rare liver disease

The US Food and Drug Administration’s (FDA) advisory committee has voted unanimously in favor of the benefits of Eli Lill...

Impressions : 795

Astra’s cancer drugs impress at ASCO; Moderna’s mRESVIA becomes first mRNA RSV vaccine approved by FDA

This week saw the American Society of Clinical Oncology (ASCO) annual meeting in Chicago where cancer researchers presented det...

Impressions : 831

Lilly to invest additional US$ 5.3 bn to boost obesity drug supply; FDA panel votes against Novo’s weekly insulin

This week’s Phispers comes packed with news of investments, acquisitions, deals and trials. Eli Lilly has more than doubl...

Impressions : 1255

Astra targets US$ 80 bn revenue by 2030, invests US$ 1.5 bn in ADC plant; Lilly’s weekly insulin scores late-stage wins

In this week’s news, AstraZeneca has laid out an ambitious plan to achieve US$ 80 billion in revenue by 2030. The drugmak...

Impressions : 609

France draws US$ 2.25 bn investment from Big Pharma; Sanofi strikes US$ 1.2 bn deal with Novavax

In this week’s news, France attracted investments from pharma majors such as Sanofi, Pfizer, AstraZeneca and GSK during t...

Impressions : 922

FDA to consider psychedelic-assisted drug for treating PTSD; Novartis buys Mariana Oncology for up to US$ 1.75 bn

Last year, the US Food and Drug Administration (FDA) had published a new draft guidance for researchers investigating the use o...

Impressions : 694

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass